Aim: To compare the efficacy of ofatumumab to other disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS). Materials & methods: A network meta-analysis was conducted to determine the relative effect of ofatumumab on annualized relapse rate and confirmed disability progression at 3 months and 6 months. Results: For each outcome, ofatumumab was as effective as other highly efficacious monoclonal antibody DMTs (i.e., alemtuzumab, natalizumab and ocrelizumab). Conclusion: Ofatumumab offers beneficial outcomes for RMS by reducing relapse and disability progression risk.
Aim: To compare the efficacy of ofatumumab to other disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS). Materials & methods: A network meta-analysis was conducted to determine the relative effect of ofatumumab on annualized relapse rate and confirmed disability progression at 3 months and 6 months. Results: For each outcome, ofatumumab was as effective as other highly efficacious monoclonal antibody DMTs (i.e., alemtuzumab, natalizumab and ocrelizumab). Conclusion: Ofatumumab offers beneficial outcomes for RMS by reducing relapse and disability progression risk.
Authors: Amit Bar-Or; Heinz Wiendl; Xavier Montalban; Enrique Alvarez; Maria Davydovskaya; Silvia R Delgado; Evgeniy P Evdoshenko; Natasa Giedraitiene; Katrin Gross-Paju; Sulev Haldre; Craig E Herrman; Guillermo Izquierdo; Guntis Karelis; Fritz Leutmezer; Miroslav Mares; Jose E Meca-Lallana; Dalia Mickeviciene; Jacqueline Nicholas; Derrick S Robertson; Denis V Sazonov; Kenneth Sharlin; Bharathy Sundaram; Natalia Totolyan; Marta Vachova; Martin Valis; Morten Bagger; Dieter A Häring; Inga Ludwig; Roman Willi; Martin Zalesak; Wendy Su; Martin Merschhemke; Edward J Fox Journal: Mult Scler Date: 2021-10-04 Impact factor: 5.855